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Integrative Physiology
Hyperamylinemia Contributes to Cardiac Dysfunction in
Obesity and Diabetes
A Study in Humans and Rats
Sanda Despa, Kenneth B. Margulies, Le Chen, Anne A. Knowlton, Peter J. Havel,
Heinrich Taegtmeyer, Donald M. Bers, Florin Despa
Rationale: Hyperamylinemia is common in patients with obesity and insulin resistance, coincides with hyperin-
sulinemia, and results in amyloid deposition. Amylin amyloids are generally considered a pancreatic disorder in
type 2 diabetes. However, elevated circulating levels of amylin may also lead to amylin accumulation and
proteotoxicity in peripheral organs, including the heart.
Objective: To test whether amylin accumulates in the heart of obese and type 2 diabetic patients and to uncover
the effects of amylin accumulation on cardiac morphology and function.
Methods and Results: We compared amylin deposition in failing and nonfailing hearts from lean, obese, and
type 2 diabetic humans using immunohistochemistry and Western blots. We found significant accumulation of
large amylin oligomers, fibrils, and plaques in failing hearts from obese and diabetic patients but not in normal
hearts and failing hearts from lean, nondiabetic humans. Small amylin oligomers were even elevated in nonfailing
hearts from overweight/obese patients, suggesting an early state of accumulation. Using a rat model of
hyperamylinemia transgenic for human amylin, we observed that amylin oligomers attach to the sarcolemma,
leading to myocyte Ca2 dysregulation, pathological myocyte remodeling, and diastolic dysfunction, starting
from prediabetes. In contrast, prediabetic rats expressing the same level of wild-type rat amylin, a nonamy-
loidogenic isoform, exhibited normal heart structure and function.
Conclusions: Hyperamylinemia promotes amylin deposition in the heart, causing alterations of cardiac
myocyte structure and function. We propose that detection and disruption of cardiac amylin buildup may
be both a predictor of heart dysfunction and a novel therapeutic strategy in diabetic cardiomyopathy. (Circ
Res. 2012;110:598-608.)
Key Words: hyperinsulinemia  hyperamylinemia  diabetic cardiomyopathy  calcium  HIP rat
 UCD-T2DM rat
One-third of adults and 17% of children in the UnitedStates (from the National Center for Health Statistics,
2009) are currently obese and at high risk of developing both
type 2 diabetes and cardiovascular disease.1–3 Progression to
overt type 2 diabetes may accelerate pathological changes in
heart structure and function,4–7 independent of confounding
factors such as coronary artery disease and hypertension.1–3 It
is assumed1 that increases in body fat can affect the body’s
response to insulin, potentially leading to insulin resistance
and subsequent impaired glucose and lipid homeostasis. As
such, insulin resistance is unequivocally associated with heart
disease.1–10 However, the myocardial insulin responsiveness
in diabetic patients is surprisingly intact,11,12 suggesting that
factors secondary to insulin resistance may critically contrib-
ute to cardiac dysfunction in type 2 diabetes.5,9,10 In addition
to hyperglycemia and dyslipidemia, patients with obesity and
insulin resistance present also hyperinsulinemia and hyper-
amylinemia.13–15 Whereas the hyperinsulinemic response pre-
vents a large fraction of insulin resistant patients from
developing type 2 diabetes,1 the coincident hyperamylinemia
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leads to proteotoxicity and amyloid deposition.13,14 More than
95% of patients with type 2 diabetes stain positive for amylin
amyloids in pancreatic islets.14 Amylin deposition was also
found in kidneys of obese and type 2 diabetic patients.16
Recently,17,18 we hypothesized that hyperamylinemia may
favor cardiac amylin accumulation,17 causing alterations of
myocyte structure and function in ways that may contribute to
progressive heart failure.18
Amylin is a 4-kDa hormone coexpressed and cosecreted
with insulin by pancreatic -cells.13,14 Human amylin, also
known as islet amyloid polypeptide (IAPP), has aggregation
properties similar to prions and amyloidogenic proteins that
are associated with neurodegenerative diseases.19 At high
secretion rates, amyloidogenic proteins readily form oligom-
ers, fibrils, and amyloid plaques. It is increasingly recognized
that soluble oligomers rather than fibrils and plaques are the
most toxic species of amyloids.20–28 They attach to cellular
membranes causing Ca2 dyshomeostasis, cell dysfunction,
and apoptosis.20–28 Previous data27,28 indicated that cardiac
myocyte–restricted expression and accumulation of amy-
loidogenic peptides, such as polyglutamine27 or presenilin,28
can induce cytotoxicity and heart failure in mice. Presenilin
oligomers coimmunoprecipitated with sarcoplasmic reticu-
lum Ca-ATPase (SERCA) and altered Ca2 handling in
cardiac myocytes.28
To clarify whether amylin builds up in the heart and
whether this could be associated with cardiac failure in
obesity and type 2 diabetes, we assessed amylin deposition
in hearts from lean, obese, and type 2 diabetic humans,
with and without heart failure. Using a “humanized” rat
model of hyperamylinemia, we examined changes in
cardiac structure and function in relation with cardiac
amylin accumulation.
Methods
Detailed procedures, description of human tissue specimens and
animal models are included in the online-only Data Supplement.
Human Tissue Specimens
Failing hearts from obese, type 2 diabetic, and nondiabetic patients
were obtained at the time of orthotopic heart transplantation at the
Hospital of University of Pennsylvania. Nonfailing hearts from
obese and lean individuals are from organ donation. Tissue speci-
mens were obtained in accordance with institutional review board
approval. Inclusion in tissue-based studies was not restricted on the
basis of age, sex, race, or ethnic status. Heart failure etiology, body
mass index, age, sex, and state of diabetes with respect to depen-
dence on insulin and/or oral hypoglycemic agents of all cases studied
here are summarized in Online Table I.
Experimental Animals
Studies were approved by the University of California, Davis,
Animal Research Committee. Because rodent amylin is not amy-
loidogenic and rodents do not accumulate amylin amyloids,29 most
rodent models of type 2 diabetes are not adequate for this study. We
used Sprague-Dawley (SD) rats transgenic for human amylin in the
pancreatic -cells (HIP rats).30 HIP rat breeding pairs were kindly
provided by Pfizer. HIP rats show hyperamylinemia, leading to
amylin deposits in pancreatic islets and gradual decline in -cell
mass.31 They develop insulin resistance at 5 months of age and
diabetes by 10 months of age.31 As negative controls, we used obese
insulin-resistant rats expressing only wild-type, nonamyloidogenic
rat amylin, which does not form amyloids (UCD-T2DM rats).32
UCD-T2DM rats were obtained by breading obese SD rats with
Zucker Diabetic Lean rats that lack the leptin receptor defect and
have inherent ß-cell defects.32 UCD-T2DM rats exhibit insulin
resistance before the onset of diabetes,32 similar to HIP rats30 and
humans.1 In the present study, we used age-matched HIP (n17) and
UCD-T2DM (n19) rats in the prediabetic state, that is, nonfasting
blood glucose level in the 150 to 200 mg/dL range.33 Wild-type
littermates (n16) served as nondiabetic controls for HIP rats.
Age-matched SD rats (n13, Charles Rivers Laboratory) were
controls for UCD-T2DM rats.
Immunochemistry
Western blot analysis was performed on left ventricular homoge-
nates, myocyte lysates, and blood serum. Immunohistochemistry was
done on thin sections from paraffin blocks.
Insulin Signaling
Myocardial insulin responsiveness was determined by measuring the
phosphorylation level of protein kinase B (Akt) and glycogen
synthase kinase 3 (GSK3) in hearts from rats injected (IP) with
insulin (10 mU/g body weight) and euthanized 10 minutes after
injection.
Cardiac Myocyte Isolation and Ca2Measurements
Rat ventricular myocytes were isolated by perfusion with 1 mg/mL
collagenase on a Langendorff apparatus as previously reported.34
Intracellular Ca2 level ([Ca2]i) was measured with Fura2 or Fluo4.
Activation of Ca2-Dependent
Hypertrophic Pathways
Activation of Ca2/calmodulin-dependent protein kinase II (CaMKII)-
histone deacetylase (HDAC) and calcineurin-nuclear factor of activated
T cells (NFAT) hypertrophic pathways was examined by determining
the nuclear versus cytosolic localization of HDAC4 and NFATc4 in
cardiac myocytes using immunofluorescence.
In Vivo Echocardiography and Hemodynamics
M-mode echocardiography and hemodynamic measurements were
performed as described before.35
Electron Microscopy
Aliquots of human/rat amylin aggregation reaction were imaged by
a Philips CM 12 electron microscope, as previously described.36
Statistical Analysis
Data are expressed as meanSEM. Statistical discriminations were
performed using 2-tailed unpaired Student t test, with P0.05
Non-standard Abbreviations and Acronyms
BNP brain natriuretic peptide
HDAC histone deacetylase
HIP rats type 2 diabetic rat model transgenic for human
amylin
IAPP islet amyloid polypeptide
NFAT nuclear factor of activated T cells
UCD-T2DM rats type 2 diabetic rat model expressing only wild-
type rat amylin
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considered significant. One-way ANOVA with the Dunnett post hoc
test was used when comparing multiple groups.
Results
Patients With Obesity and Type 2 Diabetes
Present Cardiac Amylin Accumulation
We examined left ventricular tissue from 53 human hearts
divided in 5 pathologically distinct groups (Online Table I).
These included failing hearts from patients with type 2
diabetes (n25) and obese patients that developed overt type
2 diabetes within 1 year after transplantation (n8). These
hearts were expected to show significant amylin accumula-
tion. To uncover the early stage of amylin buildup in the
heart, a third group included nonfailing hearts from over-
weight/obese humans (n8). Last, nonfailing hearts from
lean, healthy patients (n5) and failing hearts from lean
patients without diabetes (n7), which should not accumu-
late amylin, served as negative controls.
To assess the level and size distribution of cardiac amylin
aggregates, we performed Western blots with an anti-amylin
antibody on left ventricular protein homogenates. We found
molecular weight bands corresponding to amylin trimers (12
kDa), tetramers (16 kDa), and 2 additional larger molecular
weight structures at 32 kDa (octamers) and 64 kDa
(16-mers) (Figure 1A through 1C). Negative controls showed
that these bands are specific (Online Figure I). Intensity
signal analysis (Figure 1D through 1F) indicated that amylin
oligomer accumulation is markedly larger in failing hearts
from patients with type 2 diabetes and overweight/obesity
than in normal hearts and failing hearts from patients without
diabetes (controls). Intriguingly, large amylin oligomers,
(32kDa) are abundant in failing hearts from diabetic and
obese patients (Figure 1A, 1B, and 1F) but not in nonfailing
hearts from overweight/obese individuals (Figure 1C and 1F).
Smaller amylin oligomers were already elevated in nonfailing
hearts from overweight/obese patients (Figure 1C through
1E), indicating an early stage of cardiac amylin accumulation.
The results are consistent with the idea that accumulation of
large amylin oligomers can induce deleterious cardiac effects.
Amylin tetramers are also present in failing hearts from
nondiabetic patients (Figure 1E), which might indicate undi-
agnosed insulin resistance in those patients (as commonly
seen in aging).
Immunohistochemistry with an anti-amylin antibody
shows large amylin deposits in failing hearts from type 2
diabetic patients (Figure 2A through 2D), similar to those
found in the pancreas of type 2 diabetic patients (Figure 2F).
Amylin plaques (Figure 2A, 2C, and 2D) and fibrillar tangles
(Figure 2B) are scattered through the entire heart. Amylin
deposits are often seen at sites with myocyte multinucleation,
variation in nuclear size and infiltrating cells, which usually
occur with fibrotic and infiltrative diseases. In contrast,
sections from normal hearts (Figure 2E) do not show amylin
deposition and structural abnormalities. To quantify the
extent of amylin deposition in large plaques and fibrils,
pellets from heart protein homogenates were treated with
formic acid and guanidine hydrochloride to partially break
down the amylin oligomers. Dot blots showed significantly
increased amylin levels (Online Figure II), indicating that
fragmenting of large amylin aggregates enhanced detection
Figure 1. A through C, Amylin oligomer
size distribution in failing (HF) and non-
failing (NF) hearts from diabetic (D) and
overweight/obese (O) patients versus
lean (L) controls. Representative (of 4
experiments) Western blots with anti-
amylin antibody of left ventricle protein
homogenates from hearts in the D-HF (A),
O-HF (B), and O-NF (C) groups. In each
case, comparisons are made with hearts
from the L-NF group. Specific molecular
weight bands correspond to amylin trim-
ers (12 kDa), tetramers (16 kDa), and 2
larger molecular weight structures at 32
kDa (octamers) and 64 kDa (16-mers). D
through F, Intensity signal analysis of the
12, 16, and the integrated 32- to 64-kDa
bands. Heart samples in the D-HF (n25),
O-HF (n8), and O-NF (n8) groups con-
tain markedly higher amylin oligomer lev-
els than the controls L-NF (n5) and L-HF
(n7). Large-size amylin octamers and
16-mers are abundantly present only in
the failing heart O-HF and D-HF groups.
*P0.05; **P0.01.
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by the anti-amylin antibody. This also implies that blots
exhibiting higher order oligomers (Figure 1) probably under-
estimate the amount of amylin in these aggregates.
Human But Not Rat Amylin Alters Cardiac
Myocyte Structure and Function Ex Vivo
Amylin oligomers elevate [Ca2]i in pancreatic -cells lead-
ing to cellular dysfunction and apoptosis.37 Similarly,
-amyloid oligomers induce neuron dysfunction and death in
Alzheimer disease through a mechanism involving increased
[Ca2]i.20,24,25 Thus, we examined Ca2 cycling in cardiac
myocytes incubated with exogenous amylin oligomers. Rat
cardiac myocytes were incubated for 2 hours with 5 or
50 mol/L exogenous human (amyloidogenic) or rat
(nonamyloidogenic) amylin. Electron microscopy showed
that at 50 mol/L and 2 hours of incubation time, human but
not rat amylin forms oligomers (Online Figure III);
50 mol/L human amylin significantly increased Ca2 tran-
sient amplitude (Figure 3A and 3C). In contrast, same
concentration of nonamyloidogenic rat amylin had only a
modest, not significant effect (Figure 3B). Incubation with
either human or rat amylin (50 mol/L) did not alter Ca2
transient decay and diastolic [Ca2]i (Online Figure IV).
This suggests that amylin does not directly affect SERCA
function.
To determine if amylin oligomers elevate [Ca2]i by
increasing sarcolemmal Ca2 permeability, we measured the
effect of human amylin oligomers on the passive sarcolem-
mal Ca2 leak. We measured the initial rate of [Ca2]i
decline on reducing [Ca2]0 from 1 mmol/L to 0, with the SR,
Na/Ca2 exchanger and sarcolemmal Ca2-ATPase
blocked (Figure 3D). Trans-sarcolemmal Ca2 leak was
significantly larger in myocytes preincubated with 50 mol/L
human amylin versus control (Figure 3E), suggesting altera-
tion of sarcolemmal processes. Incubation of isolated myo-
cytes with fluorescent human amylin showed that amylin
attaches to the sarcolemma (Online Figure V, B). Human
amylin monomers, dimers, and trimers were present in lysates
of myocytes preincubated with 50 mol/L human amylin
(Online Figure V, A), in agreement with human amylin
attachment to sarcolemma. Thus, amylin oligomers attach to
sarcolemma and raise cellular Ca2 load in cardiac myocytes,
an effect generated also in neurons25 and pancreatic
-cells.26,37
Cardiac Amylin Accumulation Alters Ca2
Cycling in HIP Rats
To test whether in vivo cardiac accumulation of human
amylin affects Ca2 cycling, we used prediabetic HIP rats.
Age-matched, prediabetic UCD-T2DM rats expressing only
the native, nonamyloidogenic rat amylin were used as nega-
tive control. Using prediabetic rats has the advantage that one
can dissociate the effect of cardiac amylin accumulation from
other confounding factors that affect cardiac Ca2 cycling
during late diabetes.7,38,39 Immunohistochemistry (Figure 4A)
and dot blots (Figure 4B) with an anti-amylin antibody that
recognizes both human and rat amylin (the latter with higher
avidity) show that amylin significantly accumulates only in
HIP rat hearts. Western blots on left ventricular homogenates
and cardiac myocyte lysates from HIP rats (Figure 4C) show
amylin multimers similar to those detected in humans (Figure
1A through 1C) in all groups. These data indicate that amylin
oligomer accumulation in HIP rat hearts starts from predia-
betes. The presence of amylin oligomers in cardiac myocyte
lysates suggests that they attach to sarcolemma and/or enter
the myocytes.
To test whether cardiac amylin accumulation affects myo-
cardial insulin responsiveness, we compared the activation
status of Akt and GSK-3, key components of the cardiac
insulin signaling pathway, in HIP, littermate control, and
UCD-T2DM rats. For this test, HIP and UCD-T2DM rats
were matched for age and nonfasting blood glucose level
(Figure 4D). The ratio between basal levels of phosphorylated
Akt and total Akt is not statistically different among the three
groups (Figure 4E and 4F). Insulin stimulation significantly
increased the phosphorylation of Akt in all rats and no
Figure 2. Amylin deposition in failing
diabetic hearts demonstrated by immu-
nohistochemistry with an anti-amylin
antibody on thin heart sections. Amylin
plaques (A, C, and D, arrows) and tan-
gles (B, arrow) are scattered through the
entire heart. E, Left ventricle section from
a nonfailing heart; no amylin deposits are
revealed. F, Positive control for amylin
deposition in a pancreas from a diabetic
patient.
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statistical difference was observed among HIP, UCD-T2DM,
and control groups (Figure 4E and 4F). GSK-3 displays a
similar response to stimulation by insulin (Online Figure VI).
Cardiac amylin accumulation in prediabetic HIP rats alters
myocyte Ca2 cycling (Figure 5). At low stimulation fre-
quencies, Ca2 transient amplitude is significantly larger
(4.70.5 versus 3.50.3 at 0.5 Hz) in myocytes from
prediabetic HIP rats versus control rats (Figure 5A and 5D).
In contrast, cardiac myocytes from age-matched, prediabetic
UCD-T2DM rats show no change in Ca2 transient amplitude
(Figure 5G and Online Figure VII). Thus, cardiac amylin
accumulation may be the cause for the larger Ca2 transient
amplitude in prediabetic HIP rats, in agreement with our
results using exogenous human amylin oligomers (Figure 3).
Different from littermate controls, the amplitude of Ca2
transients in myocytes from prediabetic HIP rats decreases
with increasing the stimulation frequency (negative stair-
case), so that at 2 Hz the amplitude is similar to that recorded
in control rats (Figure 5B and 5D). This is probably due to
deficiencies in Ca2 reuptake into the SR. Indeed, Ca2
transient decline, which is mostly due to SR Ca2 reuptake
via the SR Ca-ATPase (SERCA), is significantly slower in
prediabetic HIP rats versus control (0.710.07 versus
0.550.04 s at a stimulation rate of 0.5 Hz; Figure 5C and
5E). In contrast, Ca2 transient decay remains unchanged in
myocytes from age-matched, prediabetic UCD-T2DM rats
(Figure 5H). Despite slower Ca2 transient relaxation, the SR
Ca2 load, assessed as the amplitude of Ca2 transient
produced by 10 mmol/L caffeine, is similar in myocytes from
control and prediabetic HIP rats paced at 2 Hz (F/
F08.50.4 versus 8.60.5). However, the slower Ca2
transient relaxation in prediabetic HIP rats results in elevated
diastolic [Ca2]i at higher pacing rates (Figure 5B and 5F).
Diastolic [Ca2]i is unaltered in prediabetic UCD-T2DM rats
(Figure 5I). Similar to myocytes incubated with human
amylin, the sarcolemmal Ca2 leak was significantly larger in
prediabetic HIP rats versus control (41.64.5 versus
29.22.4 104  F340/F380  s1, P0.05). We infer that amy-
lin oligomers can acutely increase Ca2 leak into myocytes,
causing elevated diastolic [Ca2]i and Ca2 transients, but
that reduced SERCA function may be a longer-term effect, as
in heart failure.
HDAC and NFAT Translocation in Prediabetic
HIP Rats and Myocytes Incubated With
Human Amylin
Larger Ca2 transients and elevated diastolic [Ca2]i may
activate Ca2-dependent hypertrophic signaling, such as
CaMKII-HDAC and calciuneurin-NFAT pathways.40,41 High
[Ca2]i activates CaMKII, which phosphorylates HDAC.
Normally, HDAC represses transcriptional activation. How-
ever, HDAC phosphorylation causes its export from the
nucleus, which activates hypertrophic gene expression. In the
calcineurin-NFAT pathway, on activation by Ca2/calmodu-
lin, calcineurin dephosphorylates NFAT, causing NFAT im-
port into the nucleus, which activates hypertrophic gene
transcription. Using immunofluorescence, we found lower
nuclear-to-cytosolic ratio of HDAC4 in myocytes from pre-
diabetic HIP versus littermate controls (Figure 6A and 6C),
indicating nuclear HDAC export. In contrast, the nuclear-to-
cytosolic ratio of NFATc4 is elevated in prediabetic HIP rats
(Figure 6B and 6D), suggesting the nuclear import of NFAT.
Thus, both CaMKII-HDAC and calciuneurin-NFAT hyper-
trophic pathways may be activated in prediabetic HIP rats.
NFATc4 was also translocated to the nucleus in control rat
myocytes incubated with 50 mol/L human amylin for 2
hours (Online Figure VIII). At this concentration, human
amylin forms oligomers and fibrils and elevates Ca2 tran-
Figure 3. Exogenous human amylin oligomers increase Ca2
transient amplitude in isolated rat cardiac myocytes. A, Rep-
resentative Ca2 transient measurements in a control (top
panel) cell and a myocyte preincubated with 50 mol/L human
amylin (bottom panel). B and C, Effect of 5 and 50 mol/L of
rat (B) and human (C) amylin on Ca2 transient amplitude. Oli-
gomerization of human amylin resulted in a marked Ca2 tran-
sient increase. D, Passive sarcolemmal Ca2 leak measure-
ments as initial slope of [Ca2]i decline on reducing external
[Ca2] from 1 mmol/L to 0, with the SR, Na/Ca2 exchanger
and sarcolemmal Ca2-ATPase blocked by pretreatment with
thapsigargin, 0 Na/0 Ca2 solution and 20 mol/L carboxyeo-
sin, respectively. E, Passive trans-sarcolemmal Ca2 leak is sig-
nificantly larger in myocytes pretreated with 50 mol/L human
amylin versus control. For each group, measurements were
done on 6 myocytes from 3 different rats.
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sients, as discussed in above. The distribution of HDAC4 was
not altered by this acute amylin exposure (Online Figure
VIII). We conclude that Ca2-dependent nuclear signaling
initiated by amylin oligomers is capable of inducing hyper-
trophic transcriptional effects.
Cardiac Amylin Accumulation Accelerates Cardiac
Hypertrophy and Remodeling
Elevated natriuretic peptide levels are thought to reflect
cardiac dysfunction and have been used as a “biomarker” of
cardiac hypertrophy.42,43 We found that the level of brain
natriuretic peptide (BNP) is elevated (by 10030%) in hearts
from prediabetic HIP rats versus littermate controls and
further increases with diabetes development (Figure 6E). This
suggests hormonal alterations specific to the onset of cardiac
hypertrophy in HIP rats. In contrast, the BNP level is not
altered in prediabetic UCD-T2DM rats and only increases
after the full development of diabetes (Online Figure IX, A).
Of note, a previous study found that external human amylin
induces hypertrophy in isolated cardiac myocytes.44 How-
ever, the heart weight/body weight ratio in prediabetic HIP
rats (2.720.22 g) versus control rats (2.710.2 g) did not
change, showing the lack of overt cardiac hypertrophy in this
early disease state.
Activation of Ca2-dependent transcriptional pathways
may also alter the transcription of key Ca2 transport and
regulatory proteins, which cause further alterations in Ca2
cycling. Thus, we measured the protein expression of
SERCA, phospholamban (the endogenous SERCA inhibitor),
and Na/Ca2 exchanger, the main Ca2 extrusion pathway
in HIP rats (Figure 6F). We found that SERCA expression is
reduced by 20% and 30% in prediabetic and diabetic HIP rats,
respectively (Figure 6F). In contrast, SERCA expression was
unchanged in prediabetic UCD-T2DM rats (Online Figure
IX, B). Protein expressions of phospholamban and Na/Ca2
exchanger are unaltered in prediabetic HIP rats (Figure 6F).
Prediabetic HIP Rats Show Diastolic Dysfunction
To determine how amylin accumulation affects cardiac
function, we performed in vivo echocardiography and
hemodynamic measurements on prediabetic HIP rats
(Table). We found significantly slower relaxation (reduced
dP/dtmin values) in prediabetic HIP rats versus control.
This suggests that cardiac amylin oligomer accumulation
may accelerate the occurrence of heart dysfunction, par-
ticularly diastolic dysfunction, a typical sign of diabetic
cardiomyopathy.2–10,38,39 Furthermore, the left ventricular
end diastolic volume is increased in prediabetic HIP rats,
which, combined with the unchanged fractional shorten-
ing, suggests dilation of the heart (Table).
Discussion
We found significant accumulation of large amylin oligomers
(octamers, Figure 1A, 1B, and 1F), fibrillar tangles (Figure
Figure 4. A, Immunohistochemistry with
an anti-amylin antibody on thin heart
sections demonstrating amylin deposi-
tion in cardiac tissues from prediabetic
HIP but not UCD-T2DM rats (20). B,
Dot blots with the anti-amylin antibody
comparing total amylin level in HIP versus
UCD-T2DM rats. The first 2 dots on the
left show positive controls using 5 ng of
recombinant human (h-Amylin) and rat
(r-Amylin) amylin. The antibody binds
r-Amylin with significantly higher affinity
than h-amylin; Bottom panel shows the
average signal intensity in hearts from
prediabetic HIP versus UCD-T2DM rats.
The experiment was performed in tripli-
cate. C, Representative Western blot with
anti-amylin primary antibody on ventricu-
lar myocyte lysates from prediabetic HIP
rats, and left ventricle protein homoge-
nates from prediabetic (PD) and diabetic
(DM) HIP rats. D, Blood glucose levels in
age-matched prediabetic HIP rats (n14)
and UCD-T2DM rats (n16). E and F, Akt
phosphorylation in hearts from predia-
betic HIP and UCD-T2DM rats and litter-
mate controls under basal conditions (0
insulin) and after stimulation with insulin
(10 mU/g body weight). Representative
example (E) and mean values for the ratio
between phosphorylated and total Akt (F);
n3 rats for each group.
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2B), and plaques (Figure 2A, 2C, and 2D) in failing hearts
from patients with obesity and type 2 diabetes, but not in
normal hearts and failing hearts from lean humans without
diabetes (Figure 1C and 1F). Small amylin aggregates are
even elevated in nonfailing hearts from overweight/ obese
patients (Figure 1C through 1E), suggesting that cardiac
amylin buildup starts in the early state of insulin resistance/
prediabetes. HIP rats, which express human amylin in the
pancreas, accumulate amylin oligomers in the heart (Figure
4A through 4C) starting also in prediabetes. In prediabetic
HIP rats, the interaction of amylin oligomers with cardiac
myocytes results in larger sarcolemmal Ca2 leak and Ca2
transients (Figure 5A and 5D) leading to activation of
Ca2-mediated hypertrophic pathways (Figure 6A through
6D), pathological heart remodeling (Figure 6E and 6F), and
diastolic dysfunction (Figure 5E and 5F and the Table). In
contrast, UCD-T2DM rats, which are matched for age, blood
glucose level (Figure 4D), and myocardial insulin responsive-
ness (Figure 4E and 4F) but lack amylin deposition (Figure
4A and 4B), have normal cardiac structure (Figure 4A and
4B) and function (Figure 5G through 5I). These results
suggest that cardiac dysfunction in HIP rats is most likely an
amylin-mediated effect. Hence, hyperamylinemia and conse-
quent amylin deposition, a toxic effect generally assumed to
contribute to pancreatic -cell dysfunction and development
of type 2 diabetes,13,14,31,45,46 may also be causally implicated
in cardiac dysfunction.
Pathologically Important Form of Amylin
Conditions underlying amylin oligomerization13–15,45,46 and
proteotoxicity21,22 are complex and only poorly understood.
Amyloidogenicity of human amylin promotes the attachment
to the sarcolemma (Online Figure V, B) and oligomer
formation, 2 apparently independent processes. Small oli-
gomers develop rapidly at the sarcolemma, for example, in
only 1–2 hours (Online Figure V), which correlates with an
increase in sarcolemmal permeability to Ca2 (Figure 3D and
3E) and elevated Ca2 transients (Figure 3A and 3C), with
consequent activation of Ca2-mediated hypertrophic path-
ways (Online Figure VIII). In contrast, rat amylin, a nonamy-
loidogenic isoform of amylin29 (Online Figure III), does not
affect Ca2 cycling when incubated with cardiac myocytes
(Figure 3B). These results suggest that the oligomers may be
the pathologically important forms of amylin. Amylin oli-
gomerization at the sarcolemma may act as seeds for further
amyloid growth. Fibril growth at the membrane amplifies
structural alteration of the membrane22 and Ca2 dysregula-
tion, aggravating the deleterious effects in the heart. This
might be the case for the large amylin oligomers in the 32- to
64-kDa size range that are abundant in failing hearts from
diabetic and obese patients (Figure 1A, 1B, and 1F) and in
HIP rat hearts (Figure 4C).
There is increasing support for the toxic oligomer hypoth-
esis in amyloid-related diseases,20–28 including cardiomyop-
athies caused by other amyloidogenic proteins that infiltrate
the heart, for example, transthyretin, immunoglobulin light
Figure 5. Altered Ca2 cycling in cardiac
myocytes from prediabetic HIP but not
prediabetic UCD-T2DM rats. Representa-
tive Ca2 transients in myocytes from con-
trol (Ctl) and prediabetic (PD) HIP rats
paced at 0.5 Hz (A) and 2 Hz (B). C, Nor-
malized Ca2 transients in myocytes from
control and prediabetic HIP rats (0.5 Hz)
indicate slower Ca2 transient relaxation in
prediabetic HIP rats versus control. D,
Mean amplitude of Ca2 transients rec-
orded in cardiac myocytes from control rats
(20 myocytes, 4 rats) and prediabetic HIP
rats (18 cells, 4 rats) paced at 0.2, 0.5, 1,
and 2 Hz. At 0.2 and 0.5 Hz, Ca2 transient
amplitude is significantly larger in myocytes
from prediabetic HIP rats versus control.
This difference disappears at higher stimu-
lation frequencies. E, Ca2 transient decay
time in cardiac myocytes from control and
prediabetic HIP rats paced at 0.5 Hz. F,
Diastolic [Ca2]i in cardiac myocytes from
control rats and prediabetic HIP rats paced
at 0.2, 0.5, 1, and 2 Hz. At higher frequen-
cies, diastolic [Ca2]i is significantly higher
in myocytes from prediabetic HIP versus
control rats. G, Mean amplitude of Ca2
transients in myocytes from control rats (22
myocytes, 6 rats) and prediabetic UCD-
T2DM rats (21 cells, 4 rats) paced at 0.2,
0.5, 1, and 2 Hz. H, Ca transient decay
time in myocytes from control and predia-
betic UCD-T2DM rats paced at 0.5 Hz. I,
Diastolic [Ca2]i in myocytes from control
and prediabetic UCD-T2DM rats paced at
0.2, 0.5, 1, and 2 Hz. *P0.05.
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chain, and serum amyloid.47 Data48,49 suggest that the infil-
tration of amyloidogenic proteins in the heart may induce
cardiotoxicity even before amyloid fibril formation. More-
over, intracellular accumulation of amyloid oligomers, such
as those formed by polyglutamine27 or presenilin,28 induced
cytotoxicity and heart failure in mice. Presenilin oligomers
coimmunoprecipitated with SERCA and altered Ca2 han-
dling.28 Our data from human and HIP rat hearts suggest that
amylin oligomer accumulation in the heart, which is an
outside-inside cardiac event, is cardiotoxic and may represent
an early pathogenic mechanism linking type 2 diabetes with
cardiac dysfunction.
Cardiac Amylin Accumulation and Altered
Myocyte Ca2 Cycling
Our data show that the primary effect of cardiac amylin
oligomer accumulation is an increase in myocyte Ca2 and
Ca2 transients (schematic in Figure 7). This effect was
observed both in cardiac myocytes exposed acutely to human
amylin and in prediabetic HIP rats, which accumulate amylin
oligomers in the heart, but not in prediabetic UCD-T2DM rats
that express only nonamyloidogenic rat amylin and thus lack
cardiac oligomeric amylin accumulation. Such an effect
agrees well with previous data showing that the toxicity
associated with amyloidogenic proteins is mediated by an
initial increase in [Ca2]i.20,25,37 Whereas the mechanisms
underlying the increase of [Ca2]i are not fully elucidated,
our data suggest that an augmented passive trans-
Figure 6. HDAC4 nuclear export, NFATc4 nuclear import , reduced SERCA and increased BNP in hearts from prediabetic HIP
rats. A and B, Representative immunofluorescence images showing the distribution of HDAC4 and, respectively, NFATc4 in myocytes
from prediabetic HIP rats and age-matched WT rats. C and D, The nuclear-to-cytosolic ratio of HDAC4 (C) and NFATc4 (D) demon-
strates the nuclear export of HDAC4 and nuclear import of NFATc4 in prediabetic HIP rats. Experiments were done on more than 15
cells from 3 rats for both groups. E, Increased expression of the hypertrophic marker BNP in hearts from prediabetic (PD) and diabetic
(DM) HIP rats. F, Alterations in the protein expression of SERCA, phospholamban and Na/Ca exchanger in hearts from prediabetic and
diabetic HIP rats versus control, nondiabetic rats (Ctl). Ctl, 5 hearts; PD, 5 hearts, DM, 5 hearts.
Table. Echo and Hemodynamic Parameters in Prediabetic HIP
Rats (n6) Versus Control (n10)
Control HIP
Heart rate, bpm 20814 23117
Fractional shortening, % 66.73.4 57.82.8
LVEDD, mm 6.40.3 7.20.2*
dP/dtmax, mm Hg/s 7277247 6597672
dP/dtmin, mm Hg/s 6237411 4822344*
LVmax systolic pressure, mm Hg 1072 993*
LV end-diastolic pressure, mm Hg 6.80.8 5.81.4
LVEDD indicates left ventricular end-diastolic diameter.
*P0.05.
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sarcolemmal Ca2 flux is partly responsible. Amylin oligom-
ers may also modulate the function of Ca2 channels, as
proposed in the pathology of Alzheimer disease.20,50 Elevated
[Ca2]i is involved in transcriptional regulation and hyper-
trophic signaling in the heart.40,41 Both CaMKII-HDAC and
calciuneurin-NFAT hypertrophic pathways are activated in
cardiac myocytes from prediabetic HIP rats (Figure 6A
through 6D). Moreover, the calcineurin-NFAT pathway can
be activated even by acute exposure of isolated myocytes to
human amylin oligomers (Online Figure VIII). These data
implicate the amylin oligomers as a trigger of hypertrophic
and remodeling maladaptive changes in the heart (Figure 7).
Prediabetic HIP rats show SERCA downregulation (Figure
6F), a common occurrence in diabetic cardiomyopathy,51 and
increased level of the prohypertrophic hormone BNP (Figure
6E). SERCA downregulation causes further alterations in
cardiac myocyte Ca2 cycling by impairing Ca2 transient
relaxation, which leads to negative force-frequency relation-
ship (Figure 5D) and elevated diastolic [Ca2]i (Figure 5F).
Slower Ca2 transient relaxation and elevated diastolic
[Ca2]i may further activate the CaMKII-HDAC and
calcineurin-NFAT transcriptional regulation/hypertrophic
pathways and thus aggravate the cardiac hypertrophy and
remodeling (Figure 7). Furthermore, impaired Ca2 transient
relaxation and elevated diastolic [Ca2]i cause diastolic
dysfunction in prediabetic HIP rats (Table). None of these
alterations were present in prediabetic UCD-T2DM rats.
Alterations in function and/or expression of proteins involved
in cardiac Ca2 cycling, including SERCA, and diastolic
dysfunction have been reported in other rodent models of
type 2 diabetes, but only after the onset of full-blown type 2
diabetes.7,38,39 Thus, our data indicate that cardiac amylin
oligomer accumulation accelerates the occurrence of cardiac
dysfunction and remodeling in diabetes.
Amylin Oligomer–Induced Cardiac Phenotype
At the whole-heart level, HIP rats show pathological signs of
an infiltrative disease52 (Table). This is characterized by
diastolic dysfunction (significantly reduced dP/dtmin) and
unchanged fractional shortening, which is one type of dia-
stolic heart failure.52 Diastolic heart failure often progresses
to systolic failure. Hemodynamics and echocardiographic
measurements in HIP rats show indeed significantly reduced
maximum rate of pressure fall (dP/dtmin), an index of
diastolic dysfunction, along with unchanged fractional short-
ening (Table). The left ventricular maximum systolic pressure
is also significantly reduced in HIP rats (Table). Hence,
prediabetic HIP rats display cardiac changes resembling the
cardiac infiltrative disease in humans.52 Diastolic dysfunction
is also important in the pathogenesis of diabetic cardiomy-
opathy.2–10,38,39 The molecular mechanisms underlying di-
astolic dysfunction in diabetic patients are poorly under-
stood.2–10,38,39 Present data suggest that cardiac amylin
oligomer accumulation is linked to Ca2 dysregulation and
pathological cardiac hypertrophy, which may accelerate
the onset of diastolic dysfunction in diabetes.
The pathogenesis of diabetic cardiomyopathy is multifac-
torial and includes metabolic components2–10,38,39 that have
not been studied here. Additional work to address any
potential influences of the amylin oligomers on key metabolic
processes in the heart is needed.
In conclusion, our data show that patients with obesity and
type 2 diabetes accumulate amylin oligomers in the heart and
suggest that this accelerates the development of cardiac
dysfunction. We propose that detection and disruption of
cardiac amylin buildup may be a predictor of myocardial
dysfunction and a novel therapeutic target in diabetic
cardiomyopathy.
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Figure 7. Proposed mechanism for amylin oligomer-induced
cardiac dysfunction. Amylin oligomers elevate Ca2 transients,
which results in activation of Ca2-dependent CaMKII-HDAC
and calcineurin-NFAT transcriptional regulation/hypertrophic
pathways. This may reduce SERCA expression, which further
alters myocyte Ca2 cycling by impairing Ca2 transient relax-
ation leading to higher diastolic [Ca2]i. Impaired Ca
2 transient
relaxation and elevated diastolic [Ca2]i may further activate the
Ca2-dependent transcriptional regulation/hypertrophic path-
ways (positive feedback) and cause diastolic dysfunction in HIP
rats. With the advancement of the disease, reduced SERCA
function may cause SR unloading, consequent reduction in
Ca2 transient amplitude, and systolic dysfunction.
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Novelty and Significance
What Is Known?
● Patients with obesity and insulin resistance have elevated circulating
levels of amylin, an amyloidogenic hormone coexpressed and
cosecreted with insulin by pancreatic -cells.
● At increased concentrations, amylin readily form amyloids, which are
cytotoxic and contribute to the development of type 2 diabetes.
● The most toxic species of amylin amyloids are the soluble oligomers,
which attach to cellular membranes causing Ca2 dyshomeosta-
sis, cell dysfunction, and apoptosis.
What New Information Does This Article Contribute?
● Amylin oligomers accumulate in the heart and are associated with
cardiac failure in patients with obesity and type 2 diabetes.
● Amylin oligomer buildup in the heart of rats transgenic for human
amylin is linked to myocyte Ca2 dysregulation, pathological
cardiac hypertrophy and remodeling, and diastolic dysfunction.
● Cardiac amylin accumulation accelerates the onset of diabetic
cardiomyopathy.
Obesity and insulin resistance increase the risk for both type 2
diabetes and cardiac disease, but the underlying mechanisms
remain poorly understood. In addition to hyperglycemia and
dyslipidemia, patients with obesity and insulin resistance pres-
ent also hyperinsulinemia and hyperamylinemia. Whereas the
hyperinsulinemic response prevents a large fraction of insulin
resistant patients from developing type 2 diabetes, the coinci-
dent hyperamylinemia leads to proteotoxicity and amyloid
deposition in pancreatic islets. We show that amylin oligomers,
fibrils and plaques also accumulate in failing hearts from obese
and diabetic patients, but not in nonfailing hearts and failing
hearts from lean, nondiabetic humans. Using rats transgenic for
human amylin, we show that cardiac amylin oligomer accumu-
lation causes myocyte Ca2 dysregulation, activation of Ca2-
dependent pathological cardiac hypertrophy and remodeling,
and diastolic dysfunction. Our data suggest that cardiac amylin
accumulation accelerates the onset of diabetic cardiomyopathy.
The present results show for the first time that amylin oligomers
are a direct pathogenic link between pancreatic and cardiac
disorders and an independent contributor to the multifactorial
pathogenesis of diabetic cardiomyopathy. We propose that
detection and disruption of cardiac amylin buildup may be a
predictor of myocardial dysfunction and a novel therapeutic
target in diabetic cardiomyopathy.
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SUPPLEMENTAL MATERIAL 
 
Detailed Methods 
 
Human tissue specimens  
Heart specimens were obtained at the time of orthotopic heart transplantation at the Hospital of 
University of Pennsylvania (for failing hearts) or organ donation (for non-failing hearts) in 
accordance with the Institutional Review Board approval. Inclusion in tissue-based studies was 
not restricted on the basis of age, gender, race or ethnic status. Heart failure etiology, body mass 
index (BMI), age, gender and state of diabetes with respect to dependence on insulin and/or oral 
hypoglycemic agents of all cases studied here are summarized in the Supplemental Table.  
Human heart tissues were divided in pathologically distinct groups as follows. DM-HF 
represents the group of failing hearts (HF) from patients with overt type-2 diabetes (DM) pre-
transplantation (N=25). Both ischemic (ICM) and congestive (DCM) failing hearts were included 
in the study (Table). With few exceptions, patients in this group were either overweight, i.e. 25< 
BMI <30, (N=7) or obese, i.e. BMI ≥30, (N=14), at the date of heart transplant. Some patients in 
this group were in an advanced stage of diabetes, as they received insulin (N=17). No patient 
included had a history of ketoacidosis. Other patients in the diabetes group received oral 
hypoglycemic agents alone (N=6), prior to heart transplant. OW/OB-HF stands for failing hearts 
from overweight/obese (OW/OB) patients, i.e. BMI ≥25, (N=8). Patients in this group presented 
severely impaired glucose tolerance in response to steroid exposure at the time of heart transplant 
and developed overt diabetes within 1 year post-transplantation. The OW/OB-NF group (N=8) 
includes non-failing hearts (NF) from overweight/obese individuals. Heart samples from lean 
(L), healthy patients without heart failure, i.e. the L-NF group (N=5), and from lean patients with 
heart failure but no diabetes, i.e. the L-HF group (N=7), served as controls. The L-HF group 
corresponds to patients with advanced chronic HF of variable duration (range 0.5 to 8 years) and 
included both individuals with ischemic and nonischemic etiologies for their HF, as shown in 
Supplemental Table 1. 
Experimental Animals 
Animal studies were approved by the University of California, Davis Animal Research 
Committee. Because rodent amylin is not amyloidogenic and rodents do not accumulate amylin 
amyloids (1), most rodent models are not adequate for this study. We used Sprague-Dawley rats 
that express human amylin in the pancreatic β-cells on the insulin II promoter (HIP rats) (2). HIP 
rat breeding pairs were kindly provided by Pfizer. These rats show amylin deposits in pancreatic 
islets and gradual decline in β-cell mass leading to impaired fasting glucose at 5 months of age 
and diabetes by 10 months of age (3). As negative controls, we used obese, insulin resistant rats 
expressing only the native, non-amyloidogenic rat amylin isoform, which does not form 
amyloids (UCD-T2DM rats) (4-7). The UCD-T2DM rat model was obtained by breading obese 
Sprague-Dawley rats with Zucker Diabetic Lean rats that have inherent ß-cell defects (4). UCD-
T2DM rats exhibit hyperinsulinemia associated with insulin resistance prior to the onset of 
diabetes (4), similar to HIP rats and humans (2). The model was used for studies of 
pharmacological and surgical prevention and treatment of type-2 diabetes (5-7). Both HIP and 
UCD-T2DM rats develop diabetes on a similar time scale, as shown by longitudinal 
measurements of the pancreatic secretory function reported previously (2-4). In the present 
study, we used age matched HIP and UCD-T2DM rats in the pre-diabetic state, i.e. non-fasting 
(random) blood glucose level <200 mg/dl. Pre-diabetic male HIP (N=17) and UCD-T2DM 
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(N=19) rats were used for experiments. Wild-type littermates (N=16) served as non-diabetic controls 
for HIP rats. Age-matched SD rats (N=13, Charles Rivers Laboratory) were controls for UCD-T2DM 
rats.  
Immunochemistry 
Left ventricular tissue was homogenized in homogenization buffer containing 10 mmol/L Tris-
HCl, pH 7.4, 150 mmol/L NaCl, 0.1% sodium dodecyl sulfate, 1% TritonX-100, 1% sodium 
deoxycholate, 5 mmol/L EDTA, 1 mmol/L NaF, 1 mmol/L sodium orthovanadate and protease 
and phosphatase inhibitor cocktail (Calbiochem). Isolated cardiac mocytes were lysed in lysis 
buffer containing 1% NP-40, 150 mM NaCl, 10 mM Tris-HCl, 2 mM EGTA, 50 mM NaF and 
protease and phosphatase inhibitor cocktail (Calbiochem). Blood samples were centrifuged at 
3500 rpm to remove cellular components. Human samples were incubated with Protein A-coated 
magnetic beads (Invitrogen) for 6 hours to remove IgG, a possible source of cross-reactivity. 
Standard Western blot and dot blot experiments were performed. The following primary 
antibodies were used: polyclonal anti-amylin antibody (Peninsula) that recognizes both human 
amylin and rat amylin, polyclonal anti-BNP (Millipore), anti-SERCA monoclonal (clone 2A7-
A1 from ABR), monoclonal anti-phospholamban (Badrilla) and polyclonal anti-Na/Ca exchanger 
(Millipore). For heart samples, equal loading was verified by re-probing with anti-GAPDH. 
Signal intensity analysis was performed in Image J. For each gel, we averaged the signal 
intensity of the corresponding bands for the control samples. Then, we normalized the signal 
intensity in all lanes to this average. This procedure was repeated on at least four gels and for 
each sample the normalized signal intensity was averaged. In the end, we calculated averages 
over all the groups used. 
 Immunohistochemistry was done on thin section from paraffin blocks using the same 
anti-amylin antibody and biotinylated goat anti-rabbit IgG (Vector) as the secondary antibody.  
Cardiac insulin signaling 
To determine the insulin responsiveness of the heart, rats were fasted overnight, injected (I.P.) with 
insulin (10 mU⁄g body weight) or saline, and sacrificed 10 min after injection. Hearts were 
excised quickly and frozen in liquid nitrogen. Immunoblots were performed on heart 
homogenates with phospho-Akt-Ser473, total Akt1/2, phospho-GSK3β-Ser9 and total GSK3β 
(Cell Signaling Danvers, MA). After gel electrophoresis, proteins were transferred on PVDF 
membranes, blocked and probed with primary antibodies against phospho-Akt-Ser473 or 
phospho-GSK3β-Ser9. After developing, membranes were stripped and re-probed with 
antibodies against total Akt and total GSK3β, respectively. 
Cardiac myocyte isolation 
Rats were anesthetized by I.P. injection of Nembutal (∼1 mg/g) and hearts were excised quickly, 
placed on a Langendorff perfusion apparatus and perfused with 1 mg/ml collagenase (8). When 
the heart became flaccid, the left ventricular tissue was cut into small pieces, filtered and [Ca] in 
the cell suspension was progressively increased to 1 mM (8). The standard Tyrode’s solution 
used in these experiments contained (in mM): 140 NaCl, 4 KCl, 1 MgCl2, 10 glucose, 5 HEPES 
and 1 CaCl2 (pH=7.4).  All experiments were done at room temperature (23-25°C). 
Intracellular Ca2+ measurements 
Myocytes were plated on laminin-coated coverslips, mounted on the stage of a fluorescence 
miscroscope and loaded with Fura-AM or Fluo4-AM (10 μmol/L, for 35 min for both). Fura was 
alternately excited at 340 (F340) and 380 nm (F380) and emission was collected at 510±20 nm. 
Fluo-4 was excited at 488 nm and fluorescence collected at 535±30 nm. Data collected with 
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Fura-2 are expressed as the F340/F380 ratio and Fluo4 data are expressed as F/F0, where F0 is the 
fluorescence signal in resting myocytes. Ca2+ transients were elicited by stimulation with 
external electrodes at frequencies between 0.2 and 2 Hz. The passive trans-sarcolemmal Ca2+ 
leak was measured as the initial rate of [Ca2+]i declines upon reducing external Ca2+ from 1 to 0 
mM. Ca2+ fluxes to and from the SR were blocked by pre-treating the cells with 10 µM 
thapsigargin for 10 min whereas the Na/Ca exchanger and sarcolemmal Ca2+-ATPase were 
abolished by using 0Na+/0Ca+ solution (Na+ replaced with Li+) and adding 20 µM carboxyeosin, 
respectively. 
Activation of Ca2+-dependent hypertrophic pathways  
Activation of Ca2+/calmodulin-dependent protein kinase II-histone deacetylase (HDAC) and 
calcineurin- nuclear factor of activated T cells (NFAT) hypertrophic pathways was examined by 
determining the nuclear vs. cytosolic localization of HDAC4 and NFATc4 in cardiac myocytes. 
Cells freshly isolated from pre-diabetic HIP and age-matched WT rats were plated on laminin-
coated coveslips, fixed with paraformaldehyde, permeabilized with 0.2% Triton-100, blocked 
with 2% goat serum and labeled with polyclonal primary antibodies against HDAC4 and 
NFATc4 (Santa Cruz Biotechnology). Anti-rabbit Alexa Fluor 488 was used as secondary 
antibody and fluorescence images were collected with a laser scanning confocal microscope. The 
ratio of the average fluorescence signal in the nucleus vs. cytosol was calculated with Image J. 
In vivo echocardiography and hemodynamics 
The rats were anesthetized with 50 mg/kg ketamine and 5 mg/kg xylazine, their chests were 
shaved, and an echocardiogram was done (Acuson, Sequoia model C512, 15-MHz probe) (9). 
Two-dimensional imaging was used to identify the short-axis position. Three consecutive m-
mode images were collected in the short-axis view and saved for analysis of chamber size and 
fractional shortening. In an animal subset, while the rat was under anesthesia, a carotid artery 
catheter was passed into the left ventricle to assess pressure/volume loops (9). Fractional 
shortening, heart rate, ventricular pressure, cardiac output, dP/dt, stroke work and 
pressure/volume loops were measured. 
Electron microscopy 
To visualize the nature of the molecular entities formed by human and rat amylin at 50µM 
peptide concentration in serum, aliquots of each aggregation reaction were imaged by a Philips 
CM 12 electron microscope (10). The aliquots were deposited onto freshly glow-discharged 
carbon films. The carbon films were supported by lacy Formvar/carbon films on 200-mesh 
copper grids. Small sample drops were allowed to sit for 2 min on the carbon surfaces, and then 
excess fluid was blotted away. The carbon surfaces were then rinsed by applying 5-μL drops of 
deionized water for 1 min to remove the buffer. Finally, the samples were negatively stained by 
applying 5 μL of 1% uranyl acetate for 1 min. Electron microscopy images were recorded at 
26,000× magnification. 
Statistical Analysis 
Data are expressed as mean ± SEM.  Statistical discriminations were performed using two-tailed 
unpaired Student’s t test, with P < 0.05 considered significant. One way analysis of variance 
(ANOVA) with the Dunnett post hoc test was used when comparing multiple groups.   
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Online Figure I.  
Negative control experiments aimed at testing the specificity of the bands identified in Western 
blot analysis in Fig 1. Duplicate samples were loaded onto a gel and after blotting and blocking, 
the membrane was cut and one half was incubated with the anti-amylin antibody while the other 
half was incubated in the absence of a primary antibody. Both halves were then incubated with 
the secondary antibody and developed and imaged together. The supplemental figure shows that 
there is no cross-reactivity with the secondary antibody. 
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Online Figure II 
To estimate the amylin content in insoluble fractions from human heart protein homogenates, 
pellets were treated with formic acid, freeze dried and then the resulting powders were re-
suspended in guanidine hydrochloride. Dot blots with an anti-amylin antibody (A) showed 
significantly increased amylin levels in post-treatment versus pre-treatment samples (B). (P = 
0.02, Student’s t-test.) The test suggests that large amylin aggregates fragmented into small 
oligomers that were recognized by the anti-amylin antibody.  
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Online Figure III 
Electron microscopy of amylin oligomer formation in serum. Electron microscopy images show 
that 50 μM human amylin incubated in serum for 1h has a faster oligomerization reaction than 
rat amylin and forms oligomers and protofibrils (arrow). Oligomerization of human amylin 
resulted in a marked rise in Ca2+ transient amplitude (see Fig.3). 
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Online Figure IV 
Ca2+ transient decay (A) and diastolic [Ca2+]i (B) in control rat myocytes (Ctl) and myocytes pre-
incubated for 1-2 hours with 50 µM human (h-amylin) or rat amylin (r-amylin). 
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Online Figure V 
Human amylin attaches to cardiac myocyte sarcolemma. 
(A) Isolated rat myocytes were incubated with 50 µmol/L human amylin (+) or with PBS (−) for 
2 h at room temperature. Myocytes were then washed with PBS, lysed and immunoblots were 
performed with an anti-amylin antibody. The results show the presence of human amylin 
monomers, dimers and trimers in the group treated with human amylin. (B) Isolated rat myocytes 
were plated on glass coverslips and incubated with 20 µmol/L of fluorescent FAM-human 
amylin (AnaSpec) for 2 h. Myocytes were then washed and confocal fluorescence images were 
recorded. Data show fluorescence staining of the sarcolemma, indicating that human amylin 
binds to the myocyte membrane. 
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Online Figure VI 
GSK-3β phosphorylation in hearts from pre-diabetic HIP and UCD-T2DM  rats and littermate controls 
under basal conditions (0 insulin) and following stimulation with insulin (10 mU⁄g body weight). 
Representative example and mean values for the ratio between phosphorylated and total GSK-3β. N=3 
rats for each group. 
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Online Figure VII 
Representative Ca2+ transients in myocytes from control (Ctl) and pre-diabetic (PD) UCD-T2DM 
rats paced at 0.5 Hz and 2 Hz. 
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Online Figure VIII 
Nuclear import of NFAT and unchanged HDAC distribution in rat myocytes incubated with 50 
µmol/L human amylin for 2 h.  
The top panels show representative images from control myocytes (untreated) and cells 
incubated with human amylin (H-amylin). The bottom panels show the quantification of the 
nuclear-to-cytosolic ratio for HDAC4 and NFATc4. Experiments were done on more than 12 
cells for each group. 
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Online Figure IX 
BNP and SERCA levels in hearts from UCD-T2DM rats. 
(A) BNP level is elevated in hearts from diabetic but not in pre-diabetic UCD-T2DM rats. (B) 
SERCA expression is unchanged in hearts from pre-diabetic UCD-T2DM rats. Ctl – 5 hearts; PD 
– 5 hearts, DM – 5 hearts. 
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Online Table I. Heart failure etiology, gender, age, BMI, and state of diabetes with respect to 
hyperglycemia and dependence of insulin and/or hypoglycemics for all patients from who heart 
tissue was used in this study. 
 
Code HF 
Etiology 
Gender Age BMI 
 
 
 
 
 
 
 
DM-HF 
(Insulin) 
 
 
ICM 
 
 
 
M 
 
50 32 
58 25.7 
59 31.4 
64 36.6 
58 25.7 
 
 
 
 
DCM 
 
 
F 
 
61 28 
44 31.2 
43 40.3 
 
 
 
M 
 
45 32.2 
54 28.6 
64 25.5 
59 27.7 
67 31.2 
56 32.1 
47 35.2 
 
 
 
 
DM-HF 
(Hypoglycemics)
 
 
ICM 
 
 
 
M 
60 35 
66 20.6 
56 31 
60 20.6 
63 24.3 
 
 
DCM 
 
 
 
M 
 
38 32.1 
58 34 
66 23.1 
58 34 
F 58 28.4 
 
 
 
OW/OB-HF 
 
 
 
 
ICM 
 
 
 
 
M 
 
42 28 
58 22.7 
63 25.2 
54 23.8 
47 25.9 
63 24 
49 32.7 
F 54 29.4 
 
 
OW/OB-NF 
 
F 
 
52 24.2 
51 28 
60 31.2 
 
 
51 31.9 
43 34.1 
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M 
 
50 31.8 
52 31.2 
59 28.7 
 
 
L-NF 
F 
 
37 20.8 
33 24.3 
 
M 
 
20 23.7 
45 25.1 
46 20.1 
 
 
 
L-HF 
 
ICM 
 
 
M 
 
48 19.7 
25 22.1 
58 22.7 
 
DCM 
 
F 44 20.7 
 
M 
57 23.9 
34 19.9 
46 21.8 
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